Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2013

View Archived Issues

Researchers identify a novel variant in TREM2 associated with the late-onset form of AD

Approvals and regulatory submissions mark Johnson & Johnson's fourth quarter 2012

SHP-2 as a novel prognostic marker and therapeutic target in gastric cancer

Onyx Pharmaceuticals achieves development goals

Infinity Pharmaceuticals details plans for 2013

Sanofi patents new lysophospholipid receptor agonists

Biscayne Pharmaceuticals to advance GHRH drug research

FDA accepts Ampio Pharmaceuticals' IND for Optina

VistaGen Therapeutics completes final phase I safety study of AV-101

Takeda presents new D-amino acid oxidase inhibitors

Amorfix Life Sciences developing blood test for ALS

New alpha7 nAChR modulators disclosed by Lupin

Increased glucose tolerance and insulin sensitivity seen in Socs3 knockout mouse model

BioInvent reports first results from phase I human antibody candidate study in multiple myeloma

EntreMed begins phase II study of ENMD-2076

Teva Pharmaceutical reports topline results from second phase III study of Nuvigil

New metalloenzyme inhibitors patented by Viamet Pharmaceuticals

New MAbs targeting AXL presented by French scientists

Imaxio acquires orphan drug indicated for a congenital metabolic disease

FDA extends approval of Novartis' Exjade along with companion diagnostic

Cellmid anti-midkine antibodies show promising results in mouse model of diabetic nephropathy

FDA approves use of Avastin as part of second-line therapy for metastatic colorectal cancer

New antitumor agents disclosed at Novartis

New PDE10A inhibitors disclosed by Bristol-Myers Squibb

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...